ALSO NOTED: Archemix and Isis to collaborate; WuXi PharmaTech sees successful IPO; FDA ruling soon on Wyeth drug; and much more

> Archemix and Isis Pharmaceuticals have inked a deal to collaborate on aptamer drug discovery and development. Release

> WuXi PharmaTech can bank on a successful IPO. Its shares jumped 38 percent on its opening after it priced above expectations. Release

> An FDA ruling is looming for Wyeth's schizophrenia drug bifeprunox. Report

> A team of investigators says a new trial of an experimental stroke drug has demonstrated no effect. Report

> Jordan's Hikma Pharmaceuticals is buying Alkan Pharma in Egypt for $60.5 million. Report

> American Oriental Bioengineering is buying Guangxi Boke Pharmaceutical Company for $40 million. Release

> India's Biocon has inked a deal to commercialize Abraxis' Abraxane in India. Report

> Avexa says it is ready to launch a late-stage trial of ATC. Release

And Finally… Britain's rising rates of cancer are being linked to lifestyle choices like sunbathing, drinking and smoking. Report

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.